read this before investing in MacroGenics (MGNX)
What’s up with MacroGenics?
MacroGenics (MGNX) opened at $9.00, which means the stock is up 192.24% from yesterday’s closing price of 7.60. Today, the company has a high of $23.69 and a low of $8.31. The company has a market cap of $1.07 billion with a 52-week high of $23.69 and a 52-week low of $4.04.
What about the future for MacroGenics?
The high forecast for MacroGenics is 50.00 while the low is 6.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. MacroGenics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future.. Based on this information MGNX seems to be a safe buy.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.